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ABSTRACT
Comparing independent high-throughput gene-
expression experiments can generate hypotheses
about which gene-expression programs are
shared between particular biological processes.
Current techniques to compare expression profiles
typically involve choosing a fixed differential ex-
pression threshold to summarize results, potentially
reducing sensitivity to small but concordant
changes. We present a threshold-free algorithm
called Rank–rank Hypergeometric Overlap (RRHO).
This algorithm steps through two gene lists ranked
by the degree of differential expression observed in
two profiling experiments, successively measuring
the statistical significance of the number of
overlapping genes. The output is a graphical map
that shows the strength, pattern and bounds of cor-
relation between two expression profiles. To dem-
onstrate RRHO sensitivity and dynamic range, we
identified shared expression networks in cancer
microarray profiles driving tumor progression,
stem cell properties and response to targeted
kinase inhibition. We demonstrate how RRHO can
be used to determine which model system or drug
treatment best reflects a particular biological
or disease response. The threshold-free and graph-
ical aspects of RRHO complement other rank-based
approaches such as Gene Set Enrichment
Analysis (GSEA), for which RRHO is a 2D analog.
Rank–rank overlap analysis is a sensitive, robust
and web-accessible method for detecting and
visualizing overlap trends between two complete,
continuous gene-expression profiles. A web-based
implementation of RRHO can be accessed at
http://systems.crump.ucla.edu/rankrank/.
INTRODUCTION
Technological advancements in molecular biology provide
today’s scientist a wealth of tools to reproducibly measure
the expression of a large number of genes in a variety of
model systems and patient populations. Generating bio-
logical hypotheses from high-throughput expression
proﬁling experiments can be aided by comparing
multiple expression proﬁles to one another. For
example, gene-expression changes conserved both in
human tumors and mouse models of cancer can yield
insight into underlying molecular mechanisms driving
tumorigenesis (1). Comparing results from independently
collected proﬁling experiments is often complicated by dif-
ferences in a number of important variables—which and
how many genes are measured and by which exact probes,
which species, whether DNA, RNA or protein was
measured, etc. Thus, algorithms that compare expression
proﬁles should be as sensitive and robust as possible to
detect overlap despite experimental and biological con-
founding factors.
Current methods that compare gene-expression proﬁles
often test for correlation, overlap, or enrichment between
multiple sets of genes (‘gene set versus gene set’
approaches) (2–4). Using thresholds for differential ex-
pression, many expression analysis approaches derive
gene sets tens to hundreds of genes in size to represent
the most signiﬁcant results from what was originally a
continuous range of thousands of gene-expression differ-
ences observed in a genome-wide experiment. These gene
set expression signatures are then characterized using al-
gorithms that measure statistical enrichment for genes in
particular pathways, with particular functions or with
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available databases. The statistical signiﬁcance of enrich-
ment is typically determined using the hypergeometric dis-
tribution or equivalently the one-tailed version of Fisher’s
exact test. Alternatively, approaches such as subclass
mapping allow the comparison of clusters of genes that
have similar expression patterns within subsets of samples
in different proﬁling experiments (5). In both the gene set
and gene cluster approaches, the size of the gene list and
the number of overlapping genes calculated is dependent
on the thresholds of differential expression used to create
the representative gene sets (6). Consequently, a difﬁculty
with using these types of approaches is that determining a
representative gene set demands some statistical expertise
in determining appropriate conﬁdence thresholds.
Furthermore, genes that have small but reproducible
changes tend to be discarded when taking only the top
changing genes as representatives for genome-wide expres-
sion proﬁles.
A notable improvement on these approaches is to treat
the gene-expression data as a ranked continuum of differ-
ential expression changes rather than a truncated repre-
sentative gene set. A ‘gene set versus ranked list’ approach
was ﬁrst introduced in expression analysis through the
Gene Set Enrichment Analysis (GSEA) algorithm (7–9).
This method searches for coordinated increased or
decreased expression of biologically characterized gene
sets in a microarray gene-expression experiment. Results
of a gene-expression experiment in this case are repre-
sented as a continuous list of gene-expression changes
ranked on (i) the degree of differential expression
between two types of samples or (ii) correlation to a par-
ticular quantitative phenotype pattern across a range of
samples. This gene set to ranked list approach has allowed
for the detection of weaker signals that would be missed
by previous approaches by allowing all genes in a
gene-expression proﬁle to contribute to overlap signal in
proportion to their degree of differential expression,
instead of using a ﬁxed cutoff and equally weighting
only those genes above threshold. In particular, GSEA
facilitates the detection of small but concordant and stat-
istically signiﬁcant gene-expression changes. Thus, one
can consider a full ranked list of differentially ranked
genes as the proﬁle signature for a certain biological attri-
bute, rather than just considering the top n genes as an
otherwise unweighted representative gene set. The use of
ranked gene lists to represent gene-expression proﬁles has
been demonstrated in the GSEA-based analysis of mouse
models of cancer (1) and of the Connectivity Map (Cmap)
drug response database (10).
The GSEA approach is often used with gene sets that
are derived from continuous gene-expression proﬁles, such
as results from a microarray experiment. In a recent
example, a cross-species comparison was performed in
which transcriptome microarrays were used to analyze
global gene-expression proﬁles in a genetically engineered
mouse model of lung cancer (1). A ﬁxed size representative
gene set from this mouse model proﬁle was derived from
the top differentially expressed genes using statistical tests
designed to bound the false discovery rate (FDR). This
mouse model gene set was then compared to a continuous
human lung cancer gene-expression proﬁle using GSEA.
This allowed the authors to interrogate human lung tumor
gene-expression proﬁles by applying the standard GSEA
gene set (mouse signature) versus continuous ranked gene
list (human signature) approach to compare what began
as two continuous ranked gene lists.
By eliminating the need for applying thresholds in one
gene-expression proﬁle, GSEA can detect enrichment of
groups of related genes that would be considered weakly
differential or insigniﬁcant on their own. We reasoned that
traversing the entire range of two expression proﬁles
would even more sensitively detect overlap between the
results of two genome-wide experiments and would be es-
pecially useful in cases of weak but statistically signiﬁcant,
biologically pertinent concordance. To this end, we have
developed a threshold-free algorithm designed speciﬁcally
for continuous ranked list versus ranked list genome-wide
expression proﬁle comparisons. Our Rank–rank
Hypergeometric Overlap (RRHO) algorithm identiﬁes
and visualizes areas of signiﬁcant overlap by determining
the degree of statistical enrichment using the
hypergeometric distribution while sliding across all
possible thresholds through the two ranked lists.
Whereas applications based on converting ranked lists to
gene sets using carefully chosen thresholds remain useful,
our approach complements these algorithms by providing
more information about the strength and regions of
overlap between two data sets without truncating
gene-expression proﬁles. RRHO has been implemented
to quickly and easily provide a graphical representation
that reveals global characteristics of the relationship
between two proﬁling experiments, such as whether
upregulated or downregulated genes share more in
common or whether there is greater evidence for
anti-correlation than correlation. Eliminating the need to
statistically determine thresholds for deﬁning representa-
tive gene sets makes RRHO analysis simple to use and can
identify overlap signal that would be missed using other
approaches. The sensitivity and versatility of RRHO
analysis aid in hypothesis generation by providing a stat-
istical and graphical summary of shared gene-expression
patterns between two continuous gene-expression proﬁles.
MATERIALS AND METHODS
RRHO approach
Our algorithm can be divided into several steps (schemat-
ically illustrated in Figure 1A). First, RRHO creates
gene-expression proﬁles from the two data sets being
compared by ranking the genes measured in each experi-
ment according to their degree of differential expression.
The genes can be ranked according to any measure of
differential expression; this manuscript shows results
using a signed log10-transformed t-test P-value with the
sign denoting the direction of change, positive for
increasing in the second class of the experiment and
negative for decreasing. Other common metrics are
signal-to-noise ratios (highly related to the t-test
P-value) and fold change. Sorting the genes by these
metrics will place the signiﬁcantly increasing genes at the
e169 Nucleic Acids Research, 2010,Vol.38, No. 17 PAGE 2 OF 17Figure 1. Schematic of the RRHO algorithm. (A) Preprocessing: gene-expression proﬁles are deﬁned as continuous lists of genes ranked by their
degree of differential expression. Here, we rank by the signed log10-transformed t-test P-values between Class A and B, positive sign if the mean
expression is higher in Class B and negative if lower. Microarray probes measuring the same gene are collapsed to a single value using the most
differentially expressed probe and only genes measured in both experiments are retained. A scatter plot can be used to visualize gene ranking
similarities, particularly when the degree of overlap is high. The regression ﬁt (red line) and Spearman’s rank correlation coefﬁcient (r) for this
example are indicated. Creating the RRHO map: the hypergeometric P-value for enrichment of k overlapping genes is calculated for all possible
threshold pairs for each experiment, creating a matrix where the indices are the current rank in each experiment (s, M). The direction-signed
continued
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at the bottom with all relatively unchanging genes in the
middle. Using the rank of genes instead of the raw metric
for graphing differential expression spreads the
gene-expression changes more evenly across the range of
the plot. Second, multiple probes that measure the same
gene are collapsed to a single measurement by taking the
most differentially expressed probe as a representative
value. Data-driven supervised statistic-based collapsing
has been demonstrated to improve biological discovery
(11), but RRHO is robust to other collapsing techniques
such as choosing the probe with greatest variation across
samples. Third, genes not measured in both experiments
are discarded. The gene rankings common to both experi-
ments can be visualized using a rank-based scatter plot.
When two gene-expression proﬁles are strongly and sig-
niﬁcantly overlapping throughout, enrichment can be
observed along the diagonal of the rank–rank scatter
plot and a simple correlation coefﬁcient analysis can be
used to quantify this enrichment. However, weaker but
still statistically signiﬁcant signal can not always be as
clearly visualized using rank–rank scatter plots. Fourth,
RRHO iterates through the entire ranked gene list from
both datasets calculating if the amount of genes that are
above the current thresholds in both sublists (overlapping
genes) is signiﬁcantly more or less than would be expected
by random chance according to the hypergeometric distri-
bution. This procedure results in a matrix of
hypergeometric P-values whose dimensions are
determined by the length of the ranked lists. A step par-
ameter can be used to reduce the number of calculations
and speed up the procedure. If a step size greater than one
is used, the granularity of the graphical heatmap output
provides feedback as to the adequacy of the resolution
chosen. Fifth, this matrix is shown as a heat map
colored by the direction-signed, log10-transformed
hypergeometric P-value (positive if the overlap is more
than expected and negative if it is less). The point on the
map that has the highest absolute log10-transformed sig-
niﬁcance denotes the rank thresholds (and accordingly the
metric thresholds) on the x- and y-axis (i.e. in both experi-
ments) that would yield the most statistically signiﬁcant
set of overlapping differentially expressed genes or puta-
tively co-regulated genes. This representation allows one
to quickly observe whether there is signiﬁcant overlap
between the differentially expressed genes in both experi-
ments and where the bounds of that overlap are located.
Last, multiple hypothesis testing corrections are applied as
described below. RRHO maps can be used in several ways
to determine the nature of the overlap between
gene-expression proﬁles, extract the optimal overlapping
gene set, and determine relative overlap within a series of
gene-expression proﬁles (Figure 1B).
Hypergeometric probability distributions
The hypergeometric distribution (equivalent to Fisher’s
one tailed exact test) describes the expected number of
successes in a sequence of draws from a ﬁnite population
without replacement. It is commonly used in the micro-
array analysis ﬁeld to determine the degree of enrichment
or overlap of particular subsets of genes (6,12–14). The
hypergeometric probability distribution is deﬁned as
follows:
hðk;s,M,NÞ¼
M
k
  
N   M
s   k
  
N
s
   ,
where k is the number of successes in the sample
(overlapping genes), s is the sample size, M is the
number of successes in the population (s and M are the
rank in each ranked list at the current rank step pair) and
N is the population size (the total length of the input
ranked lists), and the brackets indicate the binomial
coefﬁcient:
a
b
  
¼
a!
b!ða   bÞ!
A P-value is obtained from the Cumulative Distribution
Function (CDF) by integrating (summing) the probability
distribution from one extremity of the distribution to the
value of k:
Hðk;s,M,NÞ¼
P k
j¼0
hðj;s,M,NÞ k<¼   k
P s
j¼k
hðj;s,M,NÞ k >   k
8
> > > <
> > > :
where   k ¼ s M
N is the expected value for the hypergeometric
distribution. When k is more (or less) than expected, we
calculate the probability of observing k or greater (or
fewer) events. In our application, N is the total number
of genes in the ranked lists, s and M are the rank thresh-
olds and k is the number of overlapping genes (shown
schematically in Figure 1A). The –log10 P-value is
calculated and direction-signed for each pixel in the
RRHO map, with negative values indicating under
enrichment:
Rðk;s,M,NÞ   jlog10ðHðk;s,M,NÞÞj k<¼   k
+jlog10ðHðk;s,M,NÞÞj k >   k
,
 
In established pathway analysis approaches, s and M are
the size of a gene set derived from gene-expression experi-
ments or of a characterized gene set representing a par-
ticular signaling pathway or representing functionally
Figure 1. Continued
log10-transformed hypergeometric P-values are plotted in a heatmap as indicated by an accompanying color scale, mapping the degree of statistically
signiﬁcant overlap between the two ranked lists from that point on the map (corresponding to a rank threshold pair) to either the bottom left (ranks
0,0) or top right corner (ranks N,N). Multiple hypothesis correction can be applied using either permutation analysis (when sample number is large)
or a BY FDR correction. (B) Interpreting RRHO maps. (i) Different map patterns indicate different types of overlap, such as the full proﬁles being
correlated or only genes increasing in both experiments overlapping. (ii) The highest intensity point on the map can be used to extract the
most statistically signiﬁcant overlapping gene set. RRHO analysis can be used (iii) to compare relative overlap pairwise within a set of proﬁles
(e.g. Figures 3B and 4) or (iv) to compare an experimental proﬁle to a series of reference signatures (e.g. Figure 5).
e169 Nucleic Acids Research, 2010,Vol.38, No. 17 PAGE 4 OF 17related genes, k is the number of genes common to both
gene sets and N is an estimate of the total number of genes
from which the gene sets are chosen. Typically, k is tens to
hundreds in size, s and M are hundreds to thousands and
N is all genes measured on an expression microarray
which is on the order of tens of thousands of transcripts.
RRHO iterates through a full range of s and M sliding
through rank thresholds in two experiments, calculating
hypergeometric overlap P-values using the observed
values of overlap (k).
Mathematical symmetries of the hypergeometric
distribution. The hypergeometric CDF works well for
our application because it is symmetric upon exchange
of s and M (the two gene list rank thresholds),
Hðk;s,M,NÞ¼Hðk;M,s,NÞ. This symmetry makes the
hypergeometric CDF more suitable for our situation,
where both lists are continuous and treated in precisely
the same fashion, than metrics such as the Kolmogorov–
Smirnov statistic, which do not possess this same
symmetry upon exchange of s and M as determined by
which experiment is represented as a ranked list versus
which is represented as a ﬁxed-size gene set. An additional
symmetry of the enrichment analysis and of the
hypergeometric distribution ensures that enrichment at
the top of two lists is equivalent to enrichment at the
bottom of the two lists using the same rank threshold
points, Hðk;s,M,NÞ¼HðN   k;N   s,N   M,NÞ,s o
the calculations only need to be performed once in a
single direction. Additionally, the probability for
over-enrichment between the top of list 1 and the top of
list 2 is equal to the probability for the corresponding
under-enrichment between the top of list 1 and the
bottom of list 2, or Rðk;s,M,NÞ¼  Rðs   k;s,N   M,NÞ
due to our sign convention for over- or under-enrichment.
These characteristics aid in the computational implemen-
tation and in the interpretation of the RRHO maps
(see User’s Guide to interpreting RRHO heatmaps in
the Supplementary Data).
Computational acceleration techniques
One difﬁculty that arises from calculating P-values from
the hypergeometric distribution is the generation of
numbers with high magnitude caused by factorials. For
example, for a list of genes of moderate size, N=5000,
one would have to calculate 5000!, which is of the order
of10
16325, a number that cannot be rendered with
common representation for ﬂoating point numbers.
Furthermore, processing these high magnitude numbers
places high demands on processor time. We addressed
both problems (speed and magnitude) by using a factorial
acceleration technique (15) along with an effective imple-
mentation in the C programming language.
Factorial calculations. A factorial acceleration technique,
based on work by Trong (15), was incorporated in our C
implementation of the RRHO algorithm. The technique
uses: (i) prime number factorization of factorials and can-
cellation of common factors between numerator and de-
nominator and (ii) recursion formulas to calculate the
CDF. With this technique, we can calculate the P-values
for RRHO analysis without ever truly calculating any
factorials.
For example, consider:
hð5;10,5,20Þ¼
5!
5!ð5   5Þ!
ð20   5Þ!
ð10   5Þ!ð20   5   10+5Þ!
 
10!ð20   10Þ!
20!
¼
5!   15!   10!   10!
5!   0!   5!   10!   20!
This becomes, after prime number factorization of each
factorial and cancellation of common factors:
hð5;10,5,20Þ¼19 1   17 1   71   31   2 2 ¼ 0:0162539
We elected to use the IEEE extended double-precision
format (16) to hold ﬂoating-point numbers because
it allows for the largest exponent range (in this applica-
tion, signiﬁcant digits are of much less importance).
The current implementation of that format on our com-
puters provides: 1 sign bit, 15 bits for a signed exponent
( 16383 to 16384), and 64 bits for the mantissa.
Hence, the smallest and largest absolute numbers that
can be represented are of the order of 2
 16383
and 2
16384, respectively, corresponding to a range of ap-
proximately 10 4951.
Since the largest number that can be expressed in
extended double precision is on the order of 104951
(roughly 1760!), it is clear that additional actions are
needed to be able to treat large factorials. For that
purpose, we introduce an integer vector (dubbed the
prime-exponent vector) used to represent factorials in
which each element is the exponent of a prime number
in the factorization. For a given hypergeometric calcula-
tion, the size of the vector corresponds to the number of
prime numbers less than or equal to N. To actually
perform a hypergeometric calculation, a running-sum
prime-exponent vector is initialized with zeroes. Then
each factorial in the calculation is in turn prime-factorized
(in a vector) and added or subtracted to the running-sum
vector depending on whether the factorial is located in the
numerator or the denominator, respectively. The ﬁnal
result (probability) is obtained by carrying out this last
multiplication one factor at a time and maintaining a
running product. To avoid overﬂow or underﬂow during
the procedure, factors are not considered in their given
order. Rather, the running product is monitored and
whenever its exponent becomes too close to one of the
limits (viz.  16383 or 16384), only factors that bring
the product away from the limit are applied. The
process is repeated until all factors have been multiplied.
The ﬁnal result of the multiplication is kept in extended
double precision representation. To reduce computations,
the program uses a pre-calculated list of prime numbers
along with their log10 values.
Calculating the CDF. The calculation of the CDF involves
summing over the probability distribution from one ex-
tremity to the value of k using recursion formulas.
Recursion formulas and the prime factorization of factor-
ials are well described (15). Due to the potentially large
range in the magnitude of the numbers involved, the sum
is carried over from larger numbers toward smaller
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running sum is so small that the result would only change
less than the desired resolution.
Log-transformed (–log10) P-values are used instead of
actual P-values in the ultimate hypergeometric map visu-
alization. The log of the resulting extended
double-precision number had to be calculated with our
own function since the standard C log function accepts
only double precision arguments. The machine represen-
tation of a ﬂoating-point number x is:
x ¼ m   2e,
where m is the mantissa (a fraction) and e is the base-2
exponent. In extended double precision, the 64-bit
mantissa is stored as two 32-bits numbers (considered
unsigned integers) called m0 (most signiﬁcant digits) and
m1 (least signiﬁcant digits). Ignoring m1, we can write:
x ¼
m0
231   2e
Taking the log on both sides yields:
logðxÞ¼logðm0Þ 31   logð2Þ+e   logð2Þ,
an expression that can be calculated with the standard C
log function.
Multiple hypothesis corrections
In considering the biological implications of the
hypergeometric overlap map results, it is important to
consider multiple hypothesis correction. We have tested
two methods for multiple hypothesis correction: sample
permutation analysis and an analytical correction, a
modiﬁed Benjamini multiple hypothesis correction factor.
Permutation-based correction. Generally, we recommend
sample permutation analysis as a way of assessing the
overall signiﬁcance of a hypergeometric map. When per-
mutations are performed by randomly reassigning the
sample class labels and recalculating the ranked gene
lists, gene–gene correlations within the data are preserved
and thus this method provides a reliable estimate of how
unlikely an overlap result could be attained by random
chance (8). Note that shufﬂing gene labels instead of
sample labels does not maintain these gene–gene correl-
ations within each sample and thus simply recreates the
hypergeometric distribution. Permutation-based correc-
tion requires relatively high computation time
[O(Npermutations)] and a high enough number of samples
in each class of the proﬁling experiments to allow for suf-
ﬁcient distinct permutations. We use summary statistics of
the rank–rank overlap maps (described below) to screen
through the permutated-sample maps and determine the
frequency of permutation instances that had an optimal
overlap more signiﬁcant than in the true case to estimate
the probability of observing the true amount of overlap by
chance. For a comparison of gene lists of length 5000 and
a rank threshold step size of 50, it takes  15s to calculate
the 10000 [(5000/50)
2] hypergeometric CDF results
required to create one RRHO map using an Intel Xeon
3.2GHz processor, thus requiring  4h to create and
analyze 1000 permutation maps on a single computational
node.
We have designed summary statistics for rank–rank
hypergeometric analysis based on our experience using
gene-expression microarray data. The most straightfor-
ward summary statistic of a rank–rank hypergeometric
map is the point with the maximum absolute log
P-value, which represents the rank threshold pair that
gives the most signiﬁcant hypergeometric overlap in the
experiments being compared. When genes are ranked
using a direction-signed metric, there are often two
distinct signals in the map: one corresponding to overlap
in the tops of the lists (signal in the bottom left corner of
the RRHO map, from genes upregulated in both experi-
ments) and one corresponding to overlap in the bottoms
of the lists (top right corner, co-downregulated genes) (see
example in Figure 1B). This occurs when using lists with
overlap at each end, but little rank correlation in the
middle of the lists typically due to random ordering of
the many genes that are not differentially expressed in
the two individual experiments. In these cases, it can be
helpful to use measures that summarize the top–top and
bottom–bottom signals separately, namely the maximal
absolute log P-value in these two regions of the map
that correspond to genes changing in the same direction.
We use these two maxima both individually and as a sum
(see User-Guide Figure 2 in Supplementary Data and the
application of this approach in Figures 4 and 5).
Analytical correction: Benjamini and Yekutieli multiple
hypothesis correction. In cases where a permutation-based
correction is not feasible (when there are too few samples
for permutation analysis), we have implemented an ana-
lytical approach to apply a correction factor to account
for multiple hypothesis testing. As a multiple hypothesis
correction estimate we use the Benjamini and Yekutieli
(BY) method (17), which limits the FDR in the presence
of an arbitrary dependency structure in the tests
calculated. Our hypergeometric matrix calculates N
2
tests, where N represents the number of common genes
between the two experiments being compared. But
testing overlap in the top 50 genes in both experiments
is not independent from testing overlap in the top 100
genes as the overlap information from the top 50 is
shared between both tests. Given that the tests are not
independent, a strong family-wise error rate correction
(FWER) such as a Bonferroni correction would be pre-
dicted to be too stringent. We and others have observed
that FWER correction is in fact too stringent for overlap
and enrichment analysis techniques (8,18), for example in
comparison to permutation-based probabilities
(Supplementary Table S2). A FDR correction is more
lenient and more appropriate when there are dependencies
in the tests. BY proved that a conservative modiﬁcation of
the BY FDR correction would accommodate arbitrary
dependencies in testing (18). We have implemented this
BY correction, such that for a list of hypergeometric
P-values in increasing order:
~ pj ¼ min
k¼j,:::,N
N
k
  HN   pk
  
,
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PN
k¼1 1=k is a harmonic number and j is the
position of the P-value in the ordered list of P-values
comprising the hypergeometric map. To speed up compu-
tations, we used the fact that Hn can be approximated
through a limited asymptotic expansion: HN &g+l n
(N) where g is the Euler–Mascheroni constant.
In practice we have found that the BY correction is not
stringent enough in comparison to permutation-based cor-
rection (Supplementary Table S2). Nevertheless the BY
correction provides a computationally quick ﬁrst
estimate prior to permutations, or when permutations
are not feasible. For a direct comparison of all multiple
hypothesis correction approaches and discussion about
their appropriate use, please refer to the User’s Guide to
interpreting RRHO heatmaps in the Supplementary Data.
Note that RRHO maps are most directly comparable
when created using the same size ranked lists since the raw
hypergeometric P-value is inﬂuenced by this parameter.
The number of genes used in creating a RRHO map is
based simply on the intersection of genes measured in both
of the experiments. When two RRHO maps are made with
two very different numbers of genes, we have developed a
‘list length correction’ method to scale RRHO map
P-values before applying the BY analytical correction
Figure 2. RRHO Maps are a sensitive method for detection and visualization of overlap in expression data. Three representations of overlapping
published cancer-related gene-expression signatures: signatures with strong (A–C), medium (D–F) and weak (G–I) overlap represented as metric
scatter plots (A, D and G), rank–rank scatter plots (B, E and H) and hypergeometric overlap maps (C, F and I). The ﬁrst row of metric scatter plots
show genes plotted by their direction-signed (up, positive; down, negative), log10-transformed t-test P-values in each experiment; genes signiﬁcantly
changing in the same direction in both experiments are in Cartesian quadrants I and III and in opposite directions in quadrants II and IV. The
Spearman’s r and Kendall’s t rank correlation coefﬁcients are indicated. The second row of rank–rank scatter plots show each gene plotted by its
rank based on this metric. This representation spreads the genes more evenly across the plot and allows for assessment of overlap by increases in
local density. The resulting plots show a higher density of genes along the diagonal in both the strong and medium overlap cases, especially at the
bottom left and top right regions. The last row shows the rank–rank hypergeometric heatmap for each of these comparisons, where the overlap is
represented statistically based on the hypergeometric distribution allowing visualization of any signal, even those that are relatively weak but
signiﬁcant. The log10-transformed hypergeometric P-values are indicated in the color scale bar with negative values indicating under-enrichment.
Sample permutation P-values based on the sum of the signal in the bottom left and top right regions are indicated (perm pval).
PAGE 7 OF 17 Nucleic Acids Research, 2010,Vol.38, No. 17 e169and subsequently comparing the maps to one another (see
Supplementary Methods in Supplementary Data).
FDR for the overlapping gene list
Once the ranks corresponding to the most statistically sig-
niﬁcant overlap between the two lists are determined, the
FDR of the observed set of overlapping genes (k) can be
determined by calculating
FDRoverlapping gene list¼
kexpected
kobserved
,
where kexpected=ðs   M=NÞ, s and M are the optimal rank
thresholds and N is the full gene list length. In cases where
the overall signature overlap is statistically signiﬁcant, the
FDR of the overlapping gene list is not always small. Thus
in applications where the genes on the overlapping list will
be studied individually, the FDR should be calculated to
help guide interpretation.
Data used in demonstration cases
The demonstration cases described below feature pub-
lished microarray gene-expression data. They were con-
verted to ranked lists by calculating t-test P-values
between the relevant sample types (classes) for each
probe, that were log10-transformed and signed to
indicate direction of change (positive for increased in
Class B, negative for increased in Class A or decreased
in Class B). Probes were annotated with current mouse
or human UniGene identiﬁers and homologs were
identiﬁed using HomoloGene; only the probe with the
highest absolute signed t-test P-value within those with
matching UniGene identiﬁers was kept in the collapsing
step. Data downloaded from Gene-expression Omnibus
(GEO) (19): MPAKT prostate cancer mouse model,
GSE1413; breast tumors with ER, PR and HER2 status,
GSE2603; MMTV-HER2/neu mouse model, GSE2528;
BCR-ABL transfected cell line, GSE10912; mammary
stem cell, GSE3711; KRAS2 overexpression cell line,
GSE3151; lung tumors with KRAS2 status, GSE3141;
imatinib treatment in leukemia patients, GSE2535;
dasatinib treatment in cell lines, GSE9633 and GSE6569;
castration and testosterone treatment in mice, GSE5901;
gedunin treatment in prostate cancer cell line, GSE5506.
Data downloaded from Array Express (20): imatinib
treatment in leukemia patients, E-MEXP-433 (21). Data
downloaded from an individual lab website: KRAS2 lung
tumors and mouse model (1), Cmap database (10). Data
communicated by collaborators: PTEN knockout prostate
cancer mouse model, Dr Shunyou Wang, laboratory of Dr
Hong Wu, UCLA (22).
RESULTS
Interpretation of RRHO graphical maps
The goal of RRHO is to identify trends in overlap between
two biological signatures deﬁned as ranked lists of differ-
ential gene expression in order to generate biological
hypotheses. RRHO analysis will identify statistically sig-
niﬁcant overlap by stepping through genes ranked by their
differential expression in two experiments, at each point
using the hypergeometric distribution to assess the signiﬁ-
cance of the number of overlapping genes observed
(Figure 1A). As shown in Figure 1B, RRHO analysis
can be used in several ways to determine the overlap
pattern and overlapping genes between two or more
gene-expression proﬁles. (i) The overlap trend described
by the overall map pattern reﬂects how the two
gene-expression proﬁles are related: highly correlated
throughout (positive signal along the diagonal), strongly
differentially expressed genes overlapping (positive signal
at the bottom left and top right corners), highly
anticorrelated throughout (negative signal along the or-
thogonal diagonal, see User’s Guide) and other
possibilities. (ii) The highest intensity point on the result-
ing overlap map corresponds to the pair of rank thresh-
olds where the observed statistical overlap between the
two gene-expression proﬁles is the strongest statistically.
In other words, the highest intensity point represents the
optimal overlap between the proﬁles in that this is the
overlap that is least likely to occur by chance. The coord-
inates of the highest intensity point are the rank in each
experiment above which are the most statistically signiﬁ-
cant set of overlapping genes. This overlapping gene set
can be extracted from RRHO analysis to be validated or
further analyzed. RRHO can be used (iii) in a pairwise
fashion to determine which in a series of gene-expression
proﬁles are most closely related to one another (e.g.
Figures 3B and 4) or (iv) to compare an uncharacterized
experimental proﬁle to a series of characterized reference
proﬁles (e.g. Figure 5). Statistically signiﬁcant overlap can
indicate that the biological samples or processes being
compared have related underlying gene-expression
programs, providing a biological lead that can be
validated in follow-up experiments.
The heatmap output of RRHO is colored by the
direction-signed log10-transformed hypergeometric
P-values so high positive intensity areas indicate highly
signiﬁcant overlap of the ranked lists and high negative
intensity indicates lower than expected overlap. Each pixel
of the RRHO map represents the overlap in the top of the
ranked lists, above the corresponding rank thresholds.
High overlap throughout the entire ranked list of both
experiments (increasing and decreasing genes) will
produce a map where high intensity signal (red) will
stretch down the diagonal between the bottom left
corner and the top right corner, indicating that the best
overlap with the top m genes in list 1 is typically with the
top m genes in list 2. High overlap in only the tops of the
lists (consistently increasing genes) will give a signal in
only the bottom left region of the map and high overlap
only in the bottoms of the lists (consistently decreasing
genes) will produce signal in only the top right region.
Since the hypergeometric calculation is applied from the
tops of both lists or equivalently from the bottoms of both
lists (see ‘Mathematical symmetries of the hypergeometric
distribution’ in ‘Materials and Methods’ section), points
on the maps should be read as indicating the degree of
statistically signiﬁcant overlap between the lists from that
point on the map (corresponding to a rank threshold pair)
to either the bottom left (rank 1, 1) or top right corner
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aspects are in the User’s Guide to interpreting RRHO
heatmaps in the Supplementary Data.
Degree of overlap: RRHO analysis is sensitive to weak
statistical signal
Gene expression similarities between biological experi-
ments span a large range of possible strengths and
patterns. We collected a series of published microarray
experiments related to molecular characteristics of breast
cancer that illustrates the wide range of overlap observed
in true biological experimentation. As background to the
breast cancer biology being studied, the similarity of
gene-expression proﬁles of loss of ER (estrogen
receptor), PR (progesterone receptor) and HER2 (ErbB
receptor family, member 2) in breast cancer has been
observed by many groups. Tumors that have loss of all
of these markers (‘triple-negative’) are associated with the
‘basal-like’ gene expression-based subclass of breast
tumors and with poor prognosis (23). The desire to under-
stand the tumor cell biology downstream of these clinical
markers has driven research groups to create genetically
engineered mouse models with altered levels of these
receptors in order to study the conserved expression
changes that result. We used microarray experiments
from two major human and mouse research studies to
characterize the relationship between these molecular
markers of breast cancer in terms of their gene-expression
proﬁles.
Rank–rank overlap maps can be used to visualize the
range of gene expression overlap between two signatures,
shown in this series of breast cancer comparisons as
strong, medium and weak correlation between molecular
subtypes of human breast cancer and a related mouse
model (Figure 2). Expression in both experiments is dis-
played using metric scatter plots, rank–rank scatter plots,
or RRHO heatmaps. The x-axis on all representations
shows the difference between ER positive to ER
negative human breast tumors (24); the y-axis shows
gene-expression proﬁles based on other mutations or
other proﬁles relevant to human breast cancer. The ﬁrst
representation, metric scatter plot (Figure 2A, D and G),
shows genes plotted by their direction-signed log10-trans-
formed P-values in Experiment 1 versus Experiment 2. In
the case of a strong overlap signal (ER loss versus
PR loss), more points are in top right and bottom left
Figure 3. RRHO identiﬁes statistically signiﬁcant overlap between expression signatures supporting or generating biological hypotheses. (A) High
overlap in gene-expression changes between mouse models of prostate neoplasia driven by PTEN and AKT, both in the PI3K signaling pathway,
identifying genes consistently modulated by two different perturbations in the same pathway during tumorigenesis [hypergeometric P-value (HP)
10
 27] (22,26). (B) Increasing overlap of castration signature with PTEN-knockout-driven prostate cancer over time (minimum HP 10
 27) (22,27).
Each map shows the overlap between non-cancerous prostate tissue following castration in a mouse (compared to prostate tissue from uncastrated
mice) and a mouse model of prostate cancer driven by PTEN loss (compared to prostate tissue from wild-type littermates). The degree of overlap
increases with time and is reversed when testosterone is given for 3 days. (C) Signiﬁcant overlap between a stem cell signature from murine mammary
glands and BCR-ABL fusion onco-protein signature (HP 10
 8) (30,31). (D) High overlap between gene-expression changes driven by overexpression
of KRAS2 oncogene in a cell line and by mutated KRAS2 in human lung tumors, identifying signaling events downstream of this oncogene that are
potentially clinically relevant and can be studied in the cell line model (HP 10
 24) (35). (E) High overlap between treatment with the small-molecule
inhibitor imatinib in two leukemia patient populations, identifying higher conﬁdence markers for drug response (HP 10
 141) (21,36). (F) Signiﬁcant
overlap between cell line-derived proﬁles from different tissue types based on sensitivity to the small-molecule inhibitor dasatinib, identifying possible
adaptation mechanisms which can be targeted for higher drug efﬁcacy (HP 10
 33) (38,39). The tick mark on each axis indicates the point in the
ranked gene-expression signature list where the direction of differential expression switches. A permutation P-value based on the sum of the signal in
bottom left and top right regions (perm pval) or when permutations are not possible the maximum of the BY-corrected RRHO map (max BY) is
indicated.
PAGE 9 OF 17 Nucleic Acids Research, 2010,Vol.38, No. 17 e169Figure 4. RRHO yields comparable signiﬁcance results to GSEA while adding a 2D perspective. (A) Schematic showing how RRHO and GSEA
have been applied for comparing two continuous expression signatures. A previous application of GSEA used statistical methods (SAM algorithm)
to choose an appropriate ﬁxed threshold to deﬁne two ‘gene sets’ of up- and downregulated genes from their mouse model of lung cancer. These gene
sets were then used in GSEA to search for overlap with the expression proﬁle from human tumors treated as a continuous lists (SAM/GSEA
approach) (1). RRHO treats both signatures as continuous by stepping through all possible threshold pairs in both ranked gene lists to create a
hypergeometric overlap map. The two algorithms use different but highly related enrichment statistics, the hypergeometric distribution P-value for
RRHO and the Kolmogorov–Smirnov statistic for GSEA (see ‘Materials and Methods’ section). Both approaches employ multiple hypothesis
corrections through either permutations or analytical corrections, performing the sliding threshold(s) step in all permutations. (B and C) RRHO
maps showing the overlap between a KRAS2-driven mouse model proﬁle (x-axes) and two human lung cancer proﬁles (y-axes), one for lung
tumorigenesis in general and one speciﬁc to KRAS2 status within tumor subgroups. Red dashed lines approximate the threshold chosen to represent
the mouse model gene set in the published GSEA-based analysis and relate to the mountain plot output produced by GSEA. (D) Comparison of
permutation P-values between the SAM/GSEA and RRHO approaches. Permutation P-values from our best recreation of Sweet-Cordero SAM/
GSEA analysis mouse model deﬁned up and down (dn) gene sets are listed juxtaposed to permutation P-values from summary statistic-based
interpretations of the RRHO maps for the same data. Up results are from analysis of genes upregulated in both experiments, and likewise for down.
Up+dn RRHO results simultaneously consider both directions by calculating the sum of the maximal absolute log P-value from both the up–up and
down–down regions of the heatmap during the permutation analysis (see ‘Materials and Methods’ section).
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strong correlation in the two experiments. In this strong
case, rank-based correlation coefﬁcients show that these
signatures are signiﬁcantly similar to one another
(Spearman coefﬁcient r=0.90 and Kendall coefﬁcient
t=0.75). In the case of a medium signal (ER loss
versus HER2 receptor loss), there are many points in
each of the regions, so it becomes harder to visualize
how signiﬁcant the number of correlated points are
compared to the uncorrelated points. When the rank of
each gene in Experiment 1 is plotted versus Experiment 2
(spreading the points more evenly across the plot in a
rank–rank scatter plot, Figure 2E), an enrichment
becomes visible along the diagonal, especially at the
bottom left and top right regions. This enrichment is
more clearly reﬂected as a positive signal in the rank–
rank hypergeometric heatmap (Figure 2F). In the case of
a weak signal, ER loss versus mouse model for HER2/
Neu-driven mammary tumors (25), enrichment cannot
be easily visualized by plotting the distribution of
P-values or ranks, thus making it necessary to use an
overlap statistic-based representation such as the
hypergeometric map. In Figure 2I, the RRHO map
shows that borderline signiﬁcant overlap is present
between the human breast cancer ER-positive signature
and the HER2 mouse model of breast cancer. Weaker
signal such as this requires additional or independent con-
ﬁrmation, but identiﬁcation of this weak signal is import-
ant for generating hypotheses for future studies.
As these examples illustrate, the RRHO approach is
able to discern weak overlap signals between expression
proﬁles and is not saturated by high, near-perfect correl-
ation. While rank-based correlation coefﬁcients will
identify overlap throughout the full ranked gene proﬁles,
RRHO is sensitive to overlap occurring only in speciﬁc
sub-regions of the proﬁles. Further analysis of the range
of overlap detectable by RRHO analysis is shown in com-
parison to the Spearman rank correlation coefﬁcient using
synthetic differential gene expression data in the
Supplementary Data (User-Guide Figure 1 and
Figure 5. Using RRHO to survey a compendium of gene-expression signatures. (A) We used both RRHO and a GSEA-based approach to compare
the overlap of a gedunin treatment gene-expression proﬁle with a panel of small molecule drug treatment signatures from the Cmap database. Mean
Cmap scores are reported for multiple instances of a single drug (x-axis) using a gedunin signature of 50 up- and 50 downregulated genes. Benjamini-
Yekutieli (BY)-corrected RRHO maps for multiple instances were created individually and combined into a composite map using a pixel-by-pixel
mean; the maximum positive or minimum negative value (whichever has higher absolute value) is reported (y-axis). The Spearman rank correlation
coefﬁcient between the overlap measures of these two scoring techniques shows overall positive correlation (r=0.46). Estimated signiﬁcance
thresholds for each algorithm are indicated with red dashed lines. (B–E) Mean BY-corrected RRHO maps showing gene-expression overlap of
gedunin with the HSP90 inhibitors celastrol (B) and 17-AAG (C), the lysosome uptake inhibitor monensin (D), and the PI3 kinase inhibitor
wortmannin (E). These drugs show statistically signiﬁcant overlap by RRHO analysis, but varying degrees of overlap by Cmap analysis. Note
that in the two cases where RRHO analysis detects signal while the GSEA-based approach does not (D and E), the maximal overlap is outside the
top 50 genes used in the GSEA-based approach (i.e. the signal is further from the lower left or upper right corner than in the other cases).
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ity demonstrated in Figure 2 is reﬂective of the range of
trends in real biological data; strong signals are generally
seen with related variables in the same biological system
while weak signals are observed when a particular
molecular or transcriptional aspect is shared between
notably different biological systems.
Demonstration of RRHO maps in biological applications
To demonstrate the utility of RRHO maps, we analyzed
several pairs of published microarray experiments relevant
to cancer biology. These proﬁles were chosen because they
address several important issues in oncology:
characterizing oncogenic cell signaling in patients and
using model systems, linking cell signaling networks with
tumorigenic cellular processes and detailing molecular
response to targeted therapies. The original experiments
were executed completely independent of one another, but
using RRHO we are able to sensitively compare the results
in a straightforward manner.
The RRHO approach can be used to identify trends
within and between signaling pathways and biological
phenotypes. Beginning with a signaling pathway
example, Figure 3A shows high overlap between mouse
models of prostate neoplasia driven by loss of the tumor
suppressor PTEN or expression of constitutively active
AKT kinase. Both of these genetic changes lead to activa-
tion of the PI3K pathway and RRHO analysis identiﬁes
genes that are consistently modulated by these two differ-
ent perturbations of the same pathway during tumorigen-
esis (22,26). Furthermore, this PTEN-loss prostate cancer
model shares overlap with a castration phenotype signa-
ture (Figure 3B) (22,27). The degree of overlap increases
with time and is reversed when exogenous testosterone is
given for 3 days. This result conﬁrms the notion that
PTEN controlled signaling pathway intrinsically regulates
androgen response (28,29) and PTEN loss may contribute
to castration resistant prostate cancer development.
Furthermore, this overlap suggests that PTEN knockout
may lead to prostate cancer by initiating the same stem
cell and growth properties required to rebuild the prostate
after damage due to androgen ablation. These results are
consistent with longer castration time course experiments
in wild-type and PTEN-knockout mice (Dr Hong Wu,
data not shown).
We identiﬁed another example of overlap between the
stem cell phenotype and a signaling signature by
comparing the gene-expression proﬁle of mammary stem
cells that can regenerate a murine mammary gland (versus
myoepithelial cells that do not have this regenerative po-
tential) to the gene-expression proﬁle activated by the
potent oncogenic kinase BCR-ABL (Figure 3C) (30,31).
This result is consistent with recent studies linking stem
cell function to transformation (31–34). The overlap
between gene-expression changes driven by particular sig-
naling mutations and those found in different cell states
provides insight into the transcriptional and molecular
mechanisms that link misregulated signaling pathways to
the phenotypes that result in disease.
Expression proﬁle overlap approaches can also be used
to characterize gene-expression patterns in human cancer
patients and the effect of targeted therapies used in the
clinic. Here, we demonstrate how RRHO analysis of ex-
pression studies can be used to help assess (i) the relevance
of a cancer model system, (ii) the degree of similarity
between two independent clinical studies and (iii) the simi-
larity between drug resistance mechanisms activated in
different tumor tissue types. First, clinical research
efforts can be advanced by designing model systems to
study important molecular characteristics seen in
patients in a reproducible, low cost, easily controlled
manner. High overlap between gene-expression changes
driven by mutated KRAS2 oncogene in human lung
tumors and by overexpression of KRAS2 in a cell line
identify signaling events downstream of this oncogene
that have in vivo relevance that can be studied effectively
in vitro (Figure 3D) (35).
Second, transcriptional responses conserved between
multiple patient cohorts can be considered in higher
regard when developing model organisms and testing
hypotheses for underlying mechanisms. By comparing
two published data sets, we found highly signiﬁcant
overlap between gene-expression proﬁles of two
BCR-ABL-driven leukemia patient populations divided
into those that did or did not respond to imatinib, a break-
through small-molecule kinase inhibitor that targets the
BCR-ABL onco-kinase (Figure 3E) (21,36). These
patient samples were collected in different hospitals by
different groups but our algorithm allows us to quickly
and easily visualize that they share many expression char-
acteristics that could be at the core of the mechanisms
driving their illness and resistance to imatinib.
Third, the effects of new drugs that are being developed
are often tested in established model systems in order to
gain insight into their modes of action and potential mech-
anisms of resistance. Here, we compare experiments
testing the effect of treatment with the second-generation
small-molecule inhibitor dasatinib, which targets both
ABL and SRC family kinases. Elevated SRC kinase
activity has been implicated in contributing to many
tumor types (37). We ﬁnd that expression proﬁles that
deﬁne dasatinib sensitivity versus resistance are conserved
in two panels of cancer cell lines, one set isolated from
breast tumors and the other from prostate tumors
(Figure 3F) (38,39). The corresponding RRHO overlap
map additionally shows that genes elevated in sensitive
cell lines share more signiﬁcant overlap than genes
elevated in resistant cell lines. These results suggest that
some mechanisms of dasatinib resistance are shared
between different tumor tissue types. As shown in the
three clinically relevant cases above, RRHO analysis can
statistically and visually characterize the shared trends
from gene-expression experiments that can build conﬁ-
dence in the relevance of model systems as well as char-
acterize drug intervention at the patient level.
An advantage of RRHO maps is quick visualization of
which parts of gene-expression proﬁles have signiﬁcant
overlap. In several examples in Figure 3, signiﬁcant
overlap signal is observed in the bottom left (increasing
in both experiments) and top right (decreasing in both)
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expressed in the same direction in both experiments, while
genes that are not differentially expressed to as high an
extent show little overlap signal (middle). In Figure 3D
and F, while both the increasing and decreasing genes
are signiﬁcantly overlapping, the genes decreasing in
both experiments show higher signiﬁcance (greater
overlap in top right corner) and thus might be of greater
interest or hold greater potential for further characteriza-
tion. Observing features of the RRHO map can allow the
biologist to focus on particular groups of differentially
expressed genes based on how signiﬁcantly they overlap
with other related proﬁling experiments. Further detail on
applying and interpreting the visual patterns in RRHO
maps can be found in the user’s guide in the
Supplementary Data.
Comparing RRHO to other rank-based approaches for
gene-expression analysis: GSEA
We next compared RRHO to another popular rank-based
approach to demonstrate the unique aspects of our
method. Sweet-Cordero et al. (1) describe their use of
the popular rank-based algorithm called GSEA to
identify a KRAS2 oncogenic kinase gene-expression sig-
nature in human lung tumors via comparison to a genet-
ically engineered mouse model of lung cancer driven by
KRAS2. As shown schematically in Figure 4A, GSEA
compares a list of genes of deﬁned size (called a gene
set) to a ranked list representing the changes observed in
all genes measured in a two-class microarray differential
expression experiment. GSEA calculates the enrichment of
a gene set in continuous ranked list using a Kolmogorov–
Smirnov statistic, which in one dimension (one varying
threshold) is highly related to the hypergeometric
P-value. We have used the hypergeometric P-value
because it is exact and symmetric in two dimensions
(two thresholds). In the previously published work, in
order to ﬁt two ranked lists to a gene set versus ranked
list approach, one ranked list was ﬁrst converted to a gene
set of top upregulated genes and a set of the top
downregulated genes. The top upregulated and top
downregulated genes from the KRAS2-driven mouse
model were chosen by minimizing the FDR of differen-
tially expressed genes within one experiment below a low,
user-deﬁned threshold using Signiﬁcance Analysis of
Microarrays (SAM) (40). Then the mouse model-deﬁned
gene sets were compared to the human cancer-deﬁned con-
tinuous ranked list using standard GSEA. Using this
adapted GSEA approach, the authors were able to
identify statistically signiﬁcant overlap that would likely
have been missed by other techniques. Allowing one data
set to be analyzed as a ranked list of all gene-expression
changes added sensitivity to detect gene-expression
overlap; RRHO allows the same threshold-free treatment
for both of two gene-expression experiments to further
improve sensitivity.
Applying RRHO to the human versus mouse KRAS
gene-expression proﬁle comparison we ﬁnd similar and
expanded results compared to the original publication.
Figure 4B and C show the RRHO overlap maps for two
human cancer populations used in the Sweet-Cordero
publication, ﬁrst comparing normal tissues to lung adeno-
carcinomas in mouse and human (B) and second
comparing the KRAS2 mouse model to gene-expression
changes between human tumors with wild-type versus
mutant KRAS2 (C). Both overlap maps would allow
you to conclude that there exists statistically signiﬁcant
overlap between this KRAS2-driven mouse model of
lung cancer and human lung cancer patient proﬁles, just
as was concluded with the adapted GSEA approach. To
compare results, we also reproduced the originally
reported SAM/GSEA analysis as closely as possible and
performed sample permutation analysis as a means of
multiple hypothesis correction. Comparing the permuta-
tion P-values from the SAM/GSEA approach to those
from the RRHO approach demonstrates that both
methods have equivalent sensitivity and are able to
detect the weak but statistically signiﬁcant cross-species
signal (Figure 4D).
In the SAM/GSEA approach, the output is a permuta-
tion P-value and a Kolmogorov–Smirnov mountain plot
illustrating the overlap between a subset of high-ranking
genes chosen to represent the mouse model proﬁle (a ﬁxed
gene set) and the range of differential gene expression in
the human data set (a continuous ranked list) (1,8). The
dotted lines in Figures 4B and C reﬂect these 1D mountain
plot results. In contrast, the hypergeometric map shows
2D results over the entire range of differentially expressed
genes in both the mouse and human data sets. The normal
lung to lung adenocarcinoma comparison (Figure 4B)
shows high overlap with the KRAS2 mouse model. Both
SAM/GSEA and RRHO show more signiﬁcant results in
genes decreasing in both data sets (permutation
P-value<0.001) than in the increasing direction. In the
second comparison, KRAS2 wild-type versus mutant
tumors, the results show signiﬁcant overlap of
concordantly increasing genes using both RRHO and
SAM/GSEA while concordantly decreasing genes have
weaker overlap (Figure 4C and D). Thus, RRHO
analysis offers similar sensitivity as the SAM/GSEA
approach, but does not require the user to determine a
threshold for one of the gene-expression signatures and
provides a 2D map summarizing the regions and degree
of overlap. These output maps aid in identifying the most
signiﬁcantly overlapping regions of two gene-expression
proﬁles as thresholds chosen considering one data set
alone may miss the overlap maximum in the 2D rank–
rank space (e.g. compare the locations of the mountain
plot dotted lines to the region of highest signiﬁcance in
Figure 4B).
Integrating RRHO with public gene-expression resources:
Cmap
Another gene expression comparison application is the
mining of compendiums of gene-expression signatures to
identify biological perturbations that share related
gene-expression programs (41). Such analysis can be
used to determine which model system or drug treatment
best reﬂects a biological response or disease process
(8,35,42–46). An example resource for signature mining
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panel of speciﬁc drug treatments (10). Mining of the Cmap
database with the accompanying analysis tool involves
entering signiﬁcantly upregulated and downregulated
genes from an expression proﬁling experiment as a
query. Then, a GSEA-like Kolmogorov–Smirnov
statistic-based procedure is used to search and score the
query genes against a panel of small molecule inhibitor
response rank-based signatures. In this analysis, the
query expression signature is converted to a truncated
gene set (algorithm guidelines recommend a query gene
set between 10 and 500 genes in size) and the compendium
signatures are ranked lists of genes—thus providing the
two input types used in GSEA analysis.
Since both the query and compendium signatures can be
represented as ranked lists, we investigated the use of
RRHO for mining of the Cmap database. This removes
the need for truncating one of the signatures using a ﬁxed
differential expression threshold and accordingly should
reduce the chance of missing a weak but statistically
signiﬁcant and biologically pertinent overlap signal due
to choosing a threshold that is either too stringent or leni-
ent. The Cmap database is stored as ranked gene lists and
thus represents a public resource that can easily be used
with the rank-based RRHO algorithm.
We demonstrate the use of RRHO with the Cmap
database using the query signature from a published
proﬁling experiment on the effect of the small molecule
drug gedunin in human prostate cancer cells (43). In this
study, treatment with the phytochemical gedunin was
queried against the Cmap database and shown to have
high correlation to inhibitors of HSP90. The HSP90 chap-
erone protein is involved in the proper folding and deg-
radation that regulates the abundance of many proteins,
including several signaling- and cancer-associated
proteins. We created a ranked gene list from the gedunin
treatment microarray experiment and used RRHO
analysis to compare it to each of the 6100 ranked gene
lists in the Cmap database, representing multiple treat-
ment conditions for 1309 different drugs. BY-corrected
RRHO maps for multiple instances of a particular drug
treatment were merged by taking the pixel-by-pixel mean
to get an overall summary map for each drug. Similarly,
mean Cmap scores were calculated for each drug using the
top 50 genes that increased and decreased by gedunin
treatment relative to controls—the exact same gedunin
signature-based gene sets used in the original Cmap
analysis (43).
Overall, we found correlation between drug signature
overlap as determined by RRHO analysis and the
GSEA-based Cmap analysis (Figure 5A). In particular,
we validated the high overlap of gedunin with HSP90
inhibitors. The highest scoring overlap by both techniques
was to celastrol, another natural compound shown to
inhibit HSP90 function (Figure 5B) (43). Treatment with
the HSP90 inhibitor 7-allylamino-17-demethoxygel-
danamycin (17-AAG), highlighted in the original Cmap
publication, also has strong overlap with gedunin treat-
ment using either the RRHO or GSEA-based overlap
analysis approach (Figure 5C).
Additionally, we found drug response signatures that
had a low absolute mean Cmap GSEA-based score but
had a high mean overlap signal by RRHO analysis
(Figure 5A). One example shown in Figure 5D is the
overlap of gedunin treatment to monensin treatment, a
drug which binds to monovalent cations in the cell and
prevents uptake of proteins into the lysosome for degrad-
ation. Monensin overlap is biologically intriguing as this
drug has recently been shown to cause apoptosis synergis-
tically with the HSP90 inhibitor 17-AAG in hepatic cells
(47) and affects the release of heat shock proteins from
blood cells (48). By RRHO analysis, monensin treatment
showed comparable levels of overlap to gedunin treatment
as did 17-AAG treatment. However, since the overlap
involved some genes that were not as differentially ex-
pressed as the top 50 genes (and thus not part of the
initial Cmap 50-gene query signature for gedunin), the
mean Cmap score is quite low (0.106). The optimal
overlap hypergeometric P-value by RRHO analysis
occurs at rank position 3200 in the gedunin proﬁle, thus
the optimal overlap signal requires more genes than the
standard recommendation for Cmap query signature size.
Raising the number of upregulated genes toward the
maximum allowable by the web-application (top 950
increasing genes, top 50 decreasing genes) does increase
the Cmap score as expected (new score=0.286). This
result demonstrates the beneﬁt of not using a
pre-determined ﬁxed cutoff threshold when mining com-
pendium signature databases for biological leads.
Furthermore, we observed drug treatments that had
lower but signiﬁcant RRHO overlap scores and
near-zero Cmap scores, such as the overlap between
gedunin and wortmannin, an inhibitor of PI3 kinase
(Figure 5E). This enrichment result provides an initial
lead for further investigation since HSP90 inhibition has
an anti-apoptotic effect on cardiomyocyte damage
mediated by overactivation of the PI3K/AKT pathway
(49), and HSP90 complexes with the downstream AKT
kinase and is required for correct AKT protein folding
and stability (50–52). Instances like this of weaker but
statistically signiﬁcant overlap that can be identiﬁed by
RRHO analysis offer hypotheses related to the biological
function of targeted drug treatments like gedunin in
cancer cells.
Using RRHO maps in compendium signature mining
reveals aspects of proﬁle overlap that supplement those
provided by GSEA-based scores: (i) an overall graphical
view of the signiﬁcance of overlap for genes throughout
both ranked gene lists and (ii) the ranks in both lists that
give the highest statistical overlap, thus ensuring that
overlap signal is not missed due to choosing a query sig-
nature too stringently.
DISCUSSION
In this work, we have presented RRHO, a novel approach
for comparing gene-expression proﬁles using the
hypergeometric distribution. Our program efﬁciently tra-
verses two full gene-expression proﬁling signatures to
measure statistical signiﬁcance of overlap with high
e169 Nucleic Acids Research, 2010,Vol.38, No. 17 PAGE 14 OF 17dynamic range. Here, we have demonstrated results
obtained via RRHO that characterize biologically and
clinically relevant overlap signals between different
species, different microarray platforms, different types of
model systems and different types of molecular perturb-
ations such as drug treatment and genetic variation. In
particular, RRHO provides a straightforward and com-
prehensive method for overlap detection combined with
a graphical output that summarizes the patterns and
strengths of concordance between expression signatures
that can aide in biological hypothesis generation.
We initially developed our rank–rank algorithm to
detect weak but statistically signiﬁcant signals between
mouse models of cancer and human cancer patient
samples. An early goal was to avoid deﬁning signatures
as sets of genes truncated by user-deﬁned thresholds, but
rather to make use of the whole continuum of differential-
ly expressed genes. While the number of calculations
required to traverse the entire range of genes in two
genome-wide experiments is quite large (proportional to
the number of genes measured in both experiments
squared), RRHO features computational innovations to
make this process fast and efﬁcient. The continuum
aspect of RRHO is particularly valuable in cases of
weak overlap because it is possible to visualize where a
weak signal is at a maximum level within the range of
genes measured in both experiments and thus prevents
potential mistaken conclusions that the overlap is insig-
niﬁcant based on thresholds determined in each experi-
ment individually. General conclusions drawn from
signiﬁcant overlap patterns between two gene-expression
proﬁles, or between a signature of interest and a large
panel of previously deﬁned signatures, can generate
hypotheses that can be validated by follow-up cell
biology or patient-level studies. In addition, once the
rank thresholds corresponding to maximal overlap are
identiﬁed, the resulting list of overlapping genes can be
used for gene set functional and pathway-based enrich-
ment analysis where the goal is to emphasize consistent
results between the two experiments. In parallel work, we
have applied RRHO analysis to the comparison of human
cancer and mouse cancer model signaling pathway-speciﬁc
signatures (K. Ellwood-Yen et al., manuscript in prepar-
ation) and to breast cancer signatures linked to glycolysis
metabolism and ﬂuorodeoxyglucose-positron emission
tomography (FDG-PET) imaging (N. Palaskas et al.,
submitted for publication).
Gene-expression information from microarray data
repositories such as Gene-expression Omnibus (19) and
ArrayExpress (53) as well as from more specialized re-
sources such as the drug response proﬁle database Cmap
(10) can be readily converted to ranked list inputs for our
program. Thus, RRHO can be used to mine public
gene-expression data for common trends and to aide in
the biological interpretation of new microarray experi-
ments. Using ranked lists as input for RRHO makes the
algorithm versatile in that it can compare proﬁles
generated with other technologies such as quantitative
proteomics or perform cross-platform comparisons. We
have created a web-accessible version of RRHO
(http://systems.crump.ucla.edu/rankrank/) that generates
a hypergeometric analysis and heatmap summary
comparing two experiments, entered simply as the table
of raw data with class labels. This implementation focuses
on ease of use and interpretation by users from any ﬁeld of
biology.
The RRHO approach allows fast, sensitive, and quan-
titative determination of the degree of overlap between
two genome-scale ranked gene lists. RRHO surveys the
whole range of gene-expression changes and thus avoids
missing the point of maximal overlap signal, as can occur
when using ﬁxed thresholds. In a single visualization and
with minimal data pre-processing, the rank–rank
hypergeometric output map indicates which of several
possible overlap trends is present in expression signature
comparisons and the strength of the observed trend.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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